{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:11:00Z","timestamp":1779106260218,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hypoactive sexual desire disorder (HSDD) has a significant negative impact on women's overall health and relationships with their partners. Primary analyses from the RECONNECT clinical trials demonstrated statistically significant and clinically meaningful improvements in sexual desire and related distress with bremelanotide relative to placebo in premenopausal women with HSDD. Exit surveys and patient interviews were conducted to evaluate the impact of HSDD and bremelanotide treatment from the patient's perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Upon completion of the double-blind study but before participation in the open-label extension, up to 250 participants were recruited to complete the quantitative exit survey (17 questions). A subset of up to 90 patients was invited to participate in the telephone interview (17 questions). Patients who volunteered to participate remained blinded to study drug until the survey and interviews were completed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Quantitative exit surveys were completed by 242 RECONNECT participants; 80 of these women also completed qualitative telephone exit interviews. Participants who received bremelanotide described increased feelings of sexual desire, physical arousal, and improvements in overall quality of their sexual activities in their partner relationship. In comparison, women taking placebo reported benefits that did not include the physiological responses described by women receiving bremelanotide, such as positive experiences of seeking HSDD treatment and improved communication with their partner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Exit surveys and patient interviews support the primary findings from RECONNECT and provide quantitative and qualitative assessments of the impact of HSDD on patients' quality of life and the patients' perspectives on the impact of bremelanotide. Clinical trial numbers NCT02333071, NCT02338960.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jwh.2020.8460","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T10:33:36Z","timestamp":1612434816000},"page":"587-595","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results"],"prefix":"10.1177","volume":"30","author":[{"given":"Patricia","family":"Koochaki","sequence":"first","affiliation":[{"name":"ICON plc, Loveland, Ohio, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Revicki","sequence":"additional","affiliation":[{"name":"Evidera, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Wilson","sequence":"additional","affiliation":[{"name":"Evidera, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Pokrzywinski","sequence":"additional","affiliation":[{"name":"Evidera, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[{"name":"Palatin Technologies, Inc., Cranbury, New Jersey, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johna","family":"Lucas","sequence":"additional","affiliation":[{"name":"Palatin Technologies, Inc., Cranbury, New Jersey, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Williams","sequence":"additional","affiliation":[{"name":"AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amama","family":"Sadiq","sequence":"additional","affiliation":[{"name":"AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Krop","sequence":"additional","affiliation":[{"name":"AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1020174"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2017.05.018"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.09.018"},{"key":"e_1_3_5_5_2","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV), 4th ed. Washington, DC: American Psychiatric Publishing, Inc., 1994.","edition":"4"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181898cdb"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2014.4743"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0288-1"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003514"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00483.x"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2006.09.005"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2005.00145.x"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12273"},{"key":"e_1_3_5_14_2","first-page":"S22","article-title":"Identifying HSDD in the family medicine setting","volume":"58","author":"Kingsberg SA","year":"2009","unstructured":"Kingsberg SA. Identifying HSDD in the family medicine setting. J Fam Pract, 2009; 58(7 Suppl):S22\u2013S25.","journal-title":"J Fam Pract"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2010.2152"},{"key":"e_1_3_5_16_2","unstructured":"Addyi (flibanserin) prescribing information. Bridgewater NJ: Valeant Pharmaceuticals North America LLC 2018."},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003500"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e31824d8f40"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2020.8460","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2020.8460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2020.8460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:17:32Z","timestamp":1779103052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2020.8460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1089\/jwh.2020.8460"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2020.8460","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}